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Abstract Cyclosporine A is an immunosuppressive agent that is 
used clinically in the prevention of transplant rejection and 
development of graft-versus-host disease. Recently, cyclospor-
ine A has been shown to possess anti-inflammatory properties 
and is capable of inhibiting lipopolysaccharide-induced NF-KB 
activation. Ubiquitin-mediated proteasomal proteolysis plays a 
critical role in signal-induced NF-KB activation since it regulates 
both IKB degradation and pl05 processing, it is also involved in 
the production of peptides for the assembly of MHC class I 
molecules. We report here that cylcosporine A acts as an 
uncompetitive inhibitor of the chymotrypsin-like activity of the 
20S proteasome in vitro and that it suppresses lipopolysaccha-
ride-induced IKB degradation and pl05 processing in vivo 
demonstrating that inhibition of proteasome proteolysis is the 
mechanism by which cyclosporine A prevents NF-KB activation. 
A structurally unrelated immunosuppressant, rapamycin, did not 
inhibit the 20S proteasome in vitro. 
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1. Introduction 
The multicatalytic proteinase, or the proteasome, is a highly 
conserved cellular structure that is responsible for the ATP-
dependent proteolysis of most cellular proteins [1]. The 20S 
proteasome contains the catalytic core of the complex and has 
been crystallized from the archaebacteria Thermoplasma aci-
dophilum [2]. The archaebacterial proteasome contains 14 cop-
ies of two distinct types of subunits, a and p, which form a 
cylindrical structure consisting of four stacked rings. The top 
and bottom rings contain seven a subunits each whilst the 
inner rings contain seven P subunits. A pore extends through 
the middle of the structure and contains the proteolytic active 
sites and proteins destined for degradation pass through this 
channel. The eukaryotic 20S proteasome is structurally similar 
to its bacterial counterpart; however, a major distinction be-
tween the bacterial and mammalian systems is related to its 
catalytic activities. Unlike the archaebacterial proteasome that 
primarily exhibits chymotrypsin-like proteolytic activity [3,4], 
the eukaryotic proteasome contains at least five identifiable 
protease activities. Three of these activities are similar in spe-
cificity to chymotrypsin, trypsin and peptidylglutamyl pepti-
dase. Two other activities have also been described, one ex-
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hibiting a preference for cleavage of peptide bonds on the 
carboxyl side of branched chain amino acids and the other 
toward peptide bonds between short-chain neutral amino 
acids [5]. 
Although the 20S proteasome contains the proteolytic core, 
it cannot degrade proteins in vivo unless it is complexed with 
a 19S cap, at either end of its structure, which itself contains 
multiple ATPase activities. This bigger structure is known as 
the 26S proteasome and will rapidly degrade proteins that 
have been targeted for degradation by the addition of multiple 
molecules of the 8.5-kDa polypeptide, ubiquitin (reviewed in 
[I])-
Two types of inhibitors that inhibit the proteolytic activity 
of the proteasome have been described. Certain peptide alde-
hydes have been reported that inhibit the chymotrypsin-like 
activity of the proteasome [6-8]. These are TV-acetyl-L-leucinyl-
L-leucinyl-L-norleucinal (ALLN) and a closely related com-
pound, Af-acetyl-L-leucinyl-L-leucinyl-methional (LLM) with 
a K[ of 0.14 mM. The most potent inhibitor of this type is 
a structurally related compound, A'-carbobenzoxyl-L-leucinyl-
L-leucinyl-L-norvalinal (MG115), which exhibits a K\ of 
0.021 mM. Although these peptide aldehydes are most effec-
tive against the chymotrypsin-like proteolytic activity of the 
proteasome, other studies have shown that they are non-spe-
cific protease inhibitors. More recent reports have described a 
series of potent dipeptide inhibitors that have IC50 values in 
the range of 10-100 nM range [9]. A series of ot-ketocarbonyl 
and boronic ester derived dipeptides [10] have been described 
that are also potent inhibitors of the proteasome. 
Another report describes a different class of compounds 
that exhibit specificity in inhibiting proteasome activity [11]. 
Lactacystin is a Streptomyces metabolite that specifically in-
hibits the proteolytic activity of the proteasome complex. This 
molecule was originally discovered for its ability to induce 
neurite outgrowth in a neuroblastoma cell line [12] later it 
was shown to inhibit the proliferation of several cell types 
[13]. By using radiolabelled lactacystin binding studies [14] 
have shown that lactacystin binds irreversibly to a threonine 
residue located at the amino terminus of the P subunit of 
proteasomes. 
It is now well established that the proteasome is a major 
extralysosomal proteolytic system which is involved in the 
proteolytic pathways essential for diverse cellular functions 
[8,14,15]. For example, the active form of N F - K B is a hetero-
dimer consisting of a p65 and a p50 subunit. The latter is 
present in the cytosol as an inactive precursor (pl05). The 
proteolytic processing of pl05 to generate p50 occurs via 
the ubiquitin-proteasome pathway. Additionally, processed 
p50 and p65 are maintained in the cytosol as an inactive 
complex bound to the inhibitory protein IKB. Inflammatory 
signals such as lipopolysaccharide (LPS) activate N F - K B by 
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initiating the signalling pathway leading to the degradation of 
IKB. These signals can also stimulate the processing of pl05 
into p50. Another important function of proteasomal proteol-
ysis is to generate small peptides that are presented to T-lym-
phocytes which initiate immune responses. Inhibitors of the 
proteasome have been shown to inhibit the proteolytic proc-
esses that generate these peptides and thus prevent the assem-
bly of MHC class I molecules [8]. 
Cyclosporine A (CsA) inhibits T-cell responses and is used 
as an immunosuppressive agent in organ transplantation and 
in preventing graft-versus-host disease. Mechanistic studies 
have shown that CsA binds to the intracellular protein, cyclo-
philin, and this binary complex inhibits the activity of calci-
neurin, a calcium- and calmodulin-dependent serine/threonine 
phosphatase [16]. Calcineurin is required for activation of the 
transcription factor, NF-AT, that binds to the IL-2 promotor 
and activates its transcription. Inhibition of calcineurin activ-
ity results in the inhibition of IL-2 gene activation in T-cells 
[16]. 
Anti-inflammatory effects of CsA have also been described 
[17]. Using animal models of IgE-dependent cutaneous inflam-
mation, it has been shown that CsA inhibits the synthesis of 
IgE-dependent TNF synthesis by mast cells. A recent report 
[18] describes the inhibitory effect of CsA upon LPS-induced 
N F - K B activation and tissue factor expression in human pe-
ripheral blood mononuclear cells. Due to the integral role that 
the proteasome plays in N F - K B activation and the peptide 
nature of CsA we decided to explore the possibility that 
CsA exherts its anti-inflammatory action, at least in part, by 
inhibition of proteasome proteolysis. We report here that CsA 
acts as an uncompetitive inhibitor of the chymotrypsin-like 
activity of the 20S proteasome in vitro and that it acts to 
suppress LPS-induced IKB degradation and pi05 processing 
in vivo thereby preventing N F - K B activation. A structurally 
unrelated immunosuppressant, rapamycin, did not inhibit the 
20S proteasome in vitro. These results support the view that 
the anti-inflammatory properties of CsA may, at least in part, 
be due to inhibition of the chymotryptic activity associated 
with the proteasome. 
2. Materials and methods 
2.1. Purification and in vitro assay of the 20S proteasome from 
bovine brain 
The 20S catalytic subunit complex of the proteasome was purified 
to homogeneity from the soluble fraction of bovine brain and assayed 
according to previously published methods [19]. The chymotryptic-
like activity of the complex was measured by monitoring the increase 
in fluorescence following cleavage of the substrate peptide succinyl-
leucine-leucine-valine-tyrosine-7-amino-4-methyl coumarin (Calbio-
chem-Novabiochem). The standard in vitro assay contained 1 ug pu-
rified 20S proteasome protein in 200 ul of reaction buffer (50 mM 
HEPES, 0.1% sodium dodecyl sulfate, pH 7.5). The proteolytic reac-
tion was initiated by the addition of 50 uM fluorogenic peptide sub-
strate and allowed to progress for 15 min at 37°C. The reaction was 
terminated by the addition of 100 ul of 100 mM acetate buffer, pH 4.0. 
The rate of proteolysis is directly proportional to the amount of 
liberated aminomethyl coumarin which was measured by fluorescent 
spectroscopy (EX37onm/EM43onm) using an Hitachi model F-2000 fluo-
rescent spectrophotomer. The tryptic-like and peptidylglutamyl pepti-
dase activities of the 20S complex [20] were assayed as described 
above using 7V-carbobenzoxyl-(D)-alanine-leucine-arginine- tyrosine-
7-amino-4-methyl coumarin and JV-carbobenzoxyl-leucine-leucine-glu-
tamine-tyrosine-7-amino-4-methyl coumarin substrates respectively. 
Peptide substrates were custom synthesized by SynPep Corp. (Dublin, 
CA). CsA and rapamycin (Sigma) were dissolved in methanol, 
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7V-acetyl-leucinyl-leucinyl-norleucinal (Sigma) was dissolved in di-
methylsulfoxide. 
2.2. Cell culture 
The RAW 264.6 murine macrophage cell line used in these studies 
was purchased from the American Type Cell Culture and was main-
tained in RPMI-1640/Dulbecco's modified Eagle medium (1:1 v/v) 
supplemented with 10% fetal bovine serum and penicillin/streptomy-
cin (Gibco-BRL) at 37°C in a tissue culture incubator. 
Monolayers of RAW cells were pretreated with CsA (25 ug/ml) for 
1 h prior to exposure to bacterial LPS serotype 0111:B4 (100 ng/ml) 
(Sigma). One hour after LPS exposure, the monolayers were washed 
3 times with phosphate-buffered saline. Whole-cell lysates for Western 
blot analysis were prepared by lysing the cell monolayer with RIPA 
buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate, 100 ug/ml PMSF, 3 U/ml aprotinin, 1 mM sodium 
orthovanadate) (Sigma). Nuclear extracts were prepared using the 
high-salt buffer extraction procedure as described [21]. 
2.3. Western blots 
Cell lysates (10 ug protein) for were first subjected to electropho-
resis using a 10-20%) gradient ready gel and a mini-protean II gel 
electrophoresis unit (Bio-Rad). Following separation, proteins were 
transferred to nitrocellulose using a mini-protean II transfer unit. Im-
munoblots were probed with either IKB (MAD 3) or N F - K B p50 
(Santa Cruz Biotechnology) antibody and developed with the BM 
Chemilunimescence Western Blotting Kit (Boehringer Mannheim). 
2.4. Electrophoretic mobility shift assay 
10 pmol of either double-stranded N F - K B (5'-AGTTGAGGG-
GACTTTCCCAGGC-3') or OCT-1 (5'-TGTCGATCGGGGCGG-
GGCGAGC-3') consensus oligonucleotide (Promega) was 5'-end la-
beled with 5 uCi [y-32P]ATP ( > 5000 Ci/mmol, New England Nuclear 
Corp, Boston, MA) by incubation with T4 polynucleotide kinase for 
1 h at 37°C. Unincorporated nucleotides were removed by passing the 
reaction mixture over a 1-ml Sephadex G-50 spin column. Binding 
assays were performed at room temperature for 1 h and consisted of 
10 ug nuclear extract protein, 1 u.g salmon sperm DNA, and 5X104 
cpm of 32P-labeled consensus oligonucleotide in the presence and 
absence of 50-fold unlabeled oligonucleotide. DNA-protein com-
plexes were resolved by 8% non-denaturing polyacrylamide gel elec-
trophoresis, the gels were dried onto filter paper and visualized by 
autoradiography. 
2.5. LPS-induced TNF synthesis 
The effect of CsA on TNF synthesis by RAW cells was examined. 
Triplicate cultures of RAW cells were pretreated with varing amounts 
of CsA for 1 h prior to the addition of LPS (100 ng/ml). One hour 
after LPS addition, the spent medium was assayed for TNF using 
ELISA (Genzyme). 
3. Results and discussion 
We have attempted to investigate a potential additional 
mechanism of action of the immunosuppressant, CsA since 
this agent is capable of inhibiting signal-induced N F - K B acti-
vation [18]. Due to the integral role that the proteasome plays 
in N F - K B we explored the possibility that CsA exherts its 
anti-inflammatory action, in part, by inhibition of proteasome 
proteolysis. Since the proteasome is also involved in the pro-
duction of peptides for antigen presentation on MHC class I 
molecules [8] it was attractive to postulate an additional mech-
anism for the immunosuppressive properties of CsA. CsA is a 
cyclic undecapeptide and many of the previously described 
inhibitors of proteasome proteolysis are themselves peptide 
in nature. 
We first asked whether CsA was capable of inhibiting the 
20S proteasome proteolytic activities in vitro. Fig. la shows 
the effect of CsA upon three of the major proteolytic activites 
of the 20S proteasome. It was found that at the two concen-
trations tested (10 and 50 ng/ml) CsA had no effect upon 
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Fig. 1. Effect of CsA and rapamycin on 20S proteasome activity. 
The effect of (a) CsA and (b) rapamycin on the three major 20S 
proteasome activities were investigated at 0, 10 and 50 ug/ml. Chy-
motryptic (solid bars), tryptic (open bars) and peptidylglutamyl 
peptidase (hatched bars). Assays were performed as described in 
Section 2. 
either the tryptic or the peptidylglutamyl peptidase activities 
of the 20S proteasome; however, CsA did inhibit the chymo-
tryptic activity of the 20S proteasome in vitro with an IC50 of 
50 ug/ml. Fig. lb shows the same analysis performed using 
rapamycin an immunosuppressant which is structurally unre-
lated to CsA showing no inhibition of the 20S proteasome 
activities. 
Fig. 2 shows the double reciprocal (Lineweaver-Burk) plot 
of l/v0 versus 1/[S] for the 20S chymotryptic assay in the 
absence or presence of CsA at 10 and 50 ug/ml. The appear-
ance of parallel lines in this plot is characteristic of an un-
competitive enzyme inhibitor whereby the presence of the in-
hibitor increases the intercept on the 1/vo ordinate without 
changing the slope of the lines. 
Next we wanted to investigate the contributing role of in-
hibition of the chymotryptic activity of the 20S proteasome in 
signal-induced N F - K B activation cells. Fig. 3a shows an im-
munoblot, probed with antibodies directed toward IKB, of 
whole-cell lysates which had been pretreated with or without 
CsA or a known inhibitor of the 20S proteasome, TV-acetyl-
leucyl-leucyl-norleucinal (ALLN) for 1 h prior to the admin-
istration of LPS (100 ng/ml) to the cultures. In the absence of 
CsA or ALLN no detectable IKB is present whilst addition of 
either CsA or ALLN is seen to prevent the LPS-induced deg-
radation of IKB since IKB is clearly detectable as the major 
immunoreactive band migrating with an apparent molecular 
weight of 43 kDa. An extended exposure of the autoradio-
gram, as shown here, also reveals the presence of high molec-
ular weight immunoreactive species in the presence of the 
inhibitor molecules corresponding to the ubiquitinated forms 
of IKB indicating that the target of inhibition, in this case, is 
with proteasomal proteolysis and not with the signal-induced 
phosphorylation and ubiquitination of IKB. Fig. 3b shows an 
immunoblot, with antibodies directed toward the p50 subunit 
of N F - K B . Cells that were exposed to LPS alone clearly show 
the presence of both p50 and its high molecular weight pre-
cursor, pl05, at both protein loading concentrations whilst 
those cells that had been exposed to CsA contained quantita-
tively more pi05 than p50 indicating that Csa had inhibited 
the signal-induced proteasome processing of pl05 into p50. 
Fig. 3c shows a gel mobility shift assay using nuclear extracts 
that had been prepared from cells that had been pretreated in 
the presence and absence of CsA for 1 h prior to the admin-
istration of LPS. In cells exposed to LPS alone, N F - K B bind-
ing activity is readily demonstrated. Specificity of this binding 
activity is demonstrated by competition with excess cold N F -
KB consensus oligonucleotide in the binding reactions and 
inclusion of an N F - K B p50 subunit antibody which causes 




Fig. 2. CsA is an uncompetitive inhibitor of the chymotrypsin-like 
activity of the 20S proteasome. Double reciprocal Lineweaver-Burke 
plots were used to determine the inhibition characteristics of CsA 
on the chymotrypsin-like activity of the 20S proteasome. Assays 
were performed using variable substrate concentrations (10-50 uM) 
with either no (■), 10 ug/ml (♦ ) or 50 u.g/ml (•) CsA as described 
in Section 2. 
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weight migrating species. In nuclear extracts prepared from 
cells that had been exposed to CsA prior to LPS, very little 
nuclear N F - K B binding activity could be demonstrated. Con-
trol electrophoretic mobility shift assays for both nuclear ex-
tracts using the OCT-1 consensus oligonucleotide demonstrate 
uniformity of protein content in the binding reactions. Taken 
together these data suggest that CsA inhibits N F - K B activa-
tion by directly inhibiting the proteolytic processes involved in 
signal-induced activation and translocation of N F - K B to the 
nucleus. 
Many studies have shown that N F - K B is involved in the 
regulation of genes that are involved in inflammatory and 
immune responses including the synthesis of proinflammatory 
cytokines such as TNF, IL-1 and IL-8 [22]. Since the data 
shown in Fig. 3 indicate that CsA inhibits N F - K B activation, 
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Fig. 4. Inhibition of LPS-induced TNF synthesis by CsA. RAW 
cells were incubated for 1 h in the presence of the indicated concen-
tration of CsA then treated for 1 h with LPS (100 ng/ml). Cell cul-
ture supernatants were harvested and analysed for TNF content by 
ELISA according to the manufacturers instructions. 
Fig. 3. Inhibition of LPS-induced proteasomal proteolysis. RAW 
eels were incubated for 1 h in the presence and absence of 25 |ig/ml 
CsA or 25 ug/ml ALLN then treated for 15 min with LPS (100 ng/ 
ml). Immunoblots of cell lysate protein were prepared and analysed 
with antibodies directed toward (a) IKB (10 ug protein) and (b) p50 
(5 or 10 ug protein). For gel mobility shift assay (c) nuclear extracts 
and binding reactions were prepared from cell monolayers that had 
been incubated for 1 h in the presence and absence of CsA 
(25 ug/ml) then treated for 30 min with LPS (100 ng/ml) as de-
scribed in Section 2. 
RAW cells was examined. Fig. 4 shows that TNF synthesis 
was inhibited by CsA in a dose-dependent manner and the 
IC50 for CsA was approximately 25 ug/ml. 
Since CsA exhibits anti-inflammatory properties and can 
inhibit N F - K B activation and TNF synthesis in mast cells 
stimulated with IgE [17], we have attempted to investigate 
its mechanism of action in this respect. Chymotryptic activity 
associated with the proteasome is inhibited by CsA and con-
sistent with this observation, activation of N F - K B is prevented 
by CsA. Thus, in addition to the inhibitory effect of CsA on 
T-cell responses to antigen, this imunosuppressive agent also 
inhibits proteasome activity and thereby prevents N F - K B ac-
tivation in stimulated eels. Expression of adhesion molecules 
(CAMs, selectins) and tissue factor, synthesis of inflammatory 
cytokines (IL-1, TNF, IL-8, etc.) are all dependent on N F - K B 
activation. These proteins are an integral part of the inflam-
matory process and it is tempting to speculate that inhibiton 
of proteasome-dependent proteolysis by CsA is responsible, at 
least in part, for the anti-inflammatory effects of this drug. 
It should be noted that the concentration of CsA required 
to inhibit proteasome-dependent proteolysis in vitro (IC50 = 50 
jig/ml) appears to be higher than that required to see an effect 
upon LPS-induced proteasome proteolysis (25 ug/ml) and 
N F - K B activation in the cell based assays described here. 
TNF synthesis by mast cells stimulated with IgE was sup-
pressed by CsA and the IC50 for inhibition was approximately 
1 Ug/ml [17]. In our studies with LPS stimulated RAW cells, 
the IC50 for inhibition of TNF synthesis was approximately 
10 ug/ml. Thus depending on the cell source and the stimulant 
used, concentrations of CsA required to inhibit a specific re-
sponse can vary. The concentration of CsA needed to inhibit 
IL-2 synthesis by a T-cell hybridoma that is stimulated with 
ionomycin and phorbol ester is approximately 1 ng/ml [23]. In 
human organ transplantation, peak blood levels needed to 
prevent transplant rejection are estimated at 2.5 ug/ml when 
the dose of intravenous CsA used was 2.7 mg/kg. When an 
oral dose is used (4.5 mg/kg), sustained peak blood levels 
ranged between 1 and 1.5 ug/ml [24]. Thus it appears that 
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the dose of CsA required to inhibit the chymotryptic activity 
of the proteasome is considerably higher than that required 
for transplant rejection. CsA is extremely hydrophobic and its 
bioavailability in vivo when bound to lipoproteins and to 
other binding proteins may be different. In the in vitro assay 
used to measure effects on proteasome activity, these in vivo 
factors are absent and this may account for the higher values 
needed to inhibit the in vitro proteolytic activity. 
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